Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Northern Montana Hospital
mi
from
Havre, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Northern Montana Hospital
mi
from
Havre, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Peter's Community Hospital
mi
from
Helena, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Peter's Community Hospital
mi
from
Helena, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Kalispell Medical Oncology
mi
from
Kalispell, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Kalispell Medical Oncology
mi
from
Kalispell, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Community Medical Hospital
mi
from
Missoula, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Community Medical Hospital
mi
from
Missoula, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Montana Cancer Specialists
mi
from
Missoula, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Montana Cancer Specialists
mi
from
Missoula, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Patrick Hospital - Community Hospital
mi
from
Missoula, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Patrick Hospital - Community Hospital
mi
from
Missoula, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Guardian Oncology and Center for Wellness
mi
from
Missoula, MT
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Guardian Oncology and Center for Wellness
mi
from
Missoula, MT
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Bismarck Cancer Center
mi
from
Bismarck, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Bismarck Cancer Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Alexius Medical Center
mi
from
Bismarck, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Alexius Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Sanford Clinic North-Fargo
mi
from
Fargo, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Sanford Clinic North-Fargo
mi
from
Fargo, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Sanford Medical Center-Fargo
mi
from
Fargo, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Sanford Medical Center-Fargo
mi
from
Fargo, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Altru Cancer Center
mi
from
Grand Forks, ND
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Altru Cancer Center
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Clinic Cancer Centers-Bowling Green
mi
from
Bowling Green, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Clinic Cancer Centers-Bowling Green
mi
from
Bowling Green, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
North Coast Cancer Care - Clyde
mi
from
Clyde, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
North Coast Cancer Care - Clyde
mi
from
Clyde, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Grandview Hospital
mi
from
Dayton, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Miami Valley Hospital
mi
from
Dayton, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Samaritan North Health Center
mi
from
Dayton, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Samaritan North Health Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Dayton CCOP
mi
from
Dayton, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Dayton CCOP
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Hematology Oncology Center Incorporated
mi
from
Elyria, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Hematology Oncology Center Incorporated
mi
from
Elyria, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Blanchard Valley Hospital
mi
from
Findlay, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Blanchard Valley Hospital
mi
from
Findlay, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Wayne Hospital
mi
from
Greenville, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Wayne Hospital
mi
from
Greenville, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Kettering Medical Center
mi
from
Kettering, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Lima Memorial Hospital
mi
from
Lima, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Lima Memorial Hospital
mi
from
Lima, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Clinic Cancer Centers-Maumee
mi
from
Maumee, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Clinic Cancer Centers-Maumee
mi
from
Maumee, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Luke's Hospital
mi
from
Maumee, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Luke's Hospital
mi
from
Maumee, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
mi
from
Maumee, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
mi
from
Maumee, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Charles Hospital
mi
from
Oregon, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Charles Hospital
mi
from
Oregon, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Clinic Cancer Centers-Oregon
mi
from
Oregon, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Clinic Cancer Centers-Oregon
mi
from
Oregon, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
North Coast Cancer Care
mi
from
Sandusky, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
North Coast Cancer Care
mi
from
Sandusky, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Flower Hospital
mi
from
Sylvania, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Children's Hospital
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Vincent Mercy Medical Center
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
University of Toledo
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
University of Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Community Hospital Oncology Program CCOP
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Community Hospital Oncology Program CCOP
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Cancer Center at Saint Anne Mercy Hospital
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Cancer Center at Saint Anne Mercy Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Clinic Cancer Centers-Toledo
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Clinic Cancer Centers-Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Upper Valley Medical Center
mi
from
Troy, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Fulton County Health Center
mi
from
Wauseon, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Fulton County Health Center
mi
from
Wauseon, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Clinton Memorial Hospital
mi
from
Wilmington, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Clinton Memorial Hospital
mi
from
Wilmington, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Greene Memorial Hospital
mi
from
Xenia, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Adventist Medical Center
mi
from
Portland, OR
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Adventist Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Medical Center
mi
from
Danville, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Medical Center-Cancer Center Hazelton
mi
from
Hazleton, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Medical Center-Cancer Center Hazelton
mi
from
Hazleton, PA
Click here to add this to my saved trials